Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia

Dickinson, M., Cherif, H., Fenaux, P., Mittelman, M., Verma, A., Portella, M. S. O., Burgess, P., Ramos, P. M., Choi, J., Platzbecker, U., on behalf of the SUPPORT study investigators
American Society of Hematology (ASH)
Published 2018